Abstract is: Ira M. Longini (born October 2, 1948) is an American biostatistician and infectious disease epidemiologist.
| human | Q5 |
| P968 | email address | ilongini@ufl.edu |
| P646 | Freebase ID | /m/012nxvcp |
| P227 | GND ID | 140334947 |
| P1960 | Google Scholar author ID | DDfPqicAAAAJ |
| P269 | IdRef ID | 140256911 |
| P213 | ISNI | 000000007965471X |
| P244 | Library of Congress authority ID | no2010078870 |
| P6634 | LinkedIn personal profile ID | ira-longini-9867a446 |
| P8189 | National Library of Israel J9U ID | 987007356675705171 |
| P1006 | Nationale Thesaurus voor Auteursnamen ID | 333557417 |
| P691 | NL CR AUT ID | jo20211121676 |
| P496 | ORCID iD | 0000-0002-2780-9382 |
| P2038 | ResearchGate profile ID | 14120782_Ira_M_Longini |
| P214 | VIAF ID | 121225751 |
| P2002 | X username | ilongini |
| P1556 | zbMATH author ID | longini.ira-m-jun |
| P166 | award received | Fellow of the American Association for the Advancement of Science | Q5442484 |
| Fellow of the American Statistical Association | Q61744587 | ||
| P69 | educated at | University of Minnesota | Q238101 |
| University of Florida | Q501758 | ||
| P108 | employer | University of Michigan | Q230492 |
| University of Florida | Q501758 | ||
| P101 | field of work | biology | Q420 |
| statistics | Q12483 | ||
| epidemiology | Q133805 | ||
| biometrics | Q177765 | ||
| P735 | given name | Ira | Q11864996 |
| Ira | Q11864996 | ||
| P1412 | languages spoken, written or signed | English | Q1860 |
| P6104 | maintained by WikiProject | WikiProject Mathematics | Q8487137 |
| P106 | occupation | biologist | Q864503 |
| statistician | Q2732142 | ||
| biostatistician | Q52899051 | ||
| epidemiologist | Q12765408 | ||
| P5008 | on focus list of Wikimedia project | WikiProject COVID-19 | Q87748614 |
| P1344 | participant in | Midas Conference 2015 | Q111526900 |
| Midas Conference 2016 | Q111526901 | ||
| Midas Conference 2017 | Q111526902 | ||
| Midas Conference 2018 | Q111526903 | ||
| Midas Conference 2019 | Q111526904 | ||
| P21 | sex or gender | male | Q6581097 |
| Q57938613 | A 4-year study of the epidemiology of Vibrio cholerae in four rural areas of Bangladesh |
| Q37071067 | A Bayesian Framework for Estimating Vaccine Efficacy per Infectious Contact |
| Q30374811 | A Bayesian model for evaluating influenza antiviral efficacy in household studies with asymptomatic infections |
| Q31171693 | A Data-Augmentation Method for Infectious Disease Incidence Data from Close Contact Groups |
| Q37187393 | A Resampling-Based Test to Detect Person-To-Person Transmission of Infectious Disease |
| Q36110100 | A hybrid EM and Monte Carlo EM algorithm and its application to analysis of transmission of infectious diseases |
| Q113266827 | A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats |
| Q43511975 | A theoretic framework to consider the effect of immunizing schoolchildren against influenza: implications for research |
| Q57110255 | A/H1N1 flu pandemic. Antiviral drugs: distinguish treatment from prophylaxis |
| Q94048779 | A39 Reconstruction of Ebola chains of transmission using sequence and epidemiological data |
| Q72580611 | AIDS: modeling epidemic control |
| Q97870448 | Achieving coordinated national immunity and cholera elimination in Haiti through vaccination: a modelling study |
| Q66679104 | An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool |
| Q57163500 | Analysis of Households in Communities |
| Q57163505 | Analysis of Independent Households |
| Q51913045 | Analytic insights into the population level impact of imperfect prophylactic HIV vaccines. |
| Q79334164 | Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials |
| Q30372938 | Antiviral resistance and the control of pandemic influenza: the roles of stochasticity, evolution and model details. |
| Q57163511 | Assessing Indirect, Total, and Overall Effects |
| Q35557090 | Assessing the impact of travel restrictions on international spread of the 2014 West African Ebola epidemic |
| Q34214619 | Assessing the international spreading risk associated with the 2014 west african ebola outbreak |
| Q28730914 | Assessing the potential of a candidate dengue vaccine with mathematical modeling |
| Q74246788 | Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy |
| Q57163515 | Binomial and Stochastic Transmission Models |
| Q52718700 | Biofilms Comprise a Component of the Annual Cycle of Vibrio cholerae in the Bay of Bengal Estuary. |
| Q99622859 | COVID-19 vaccine trials should seek worthwhile efficacy |
| Q44102519 | Changes in the primary outcome in Ebola vaccine trial--Authors' reply |
| Q35816057 | Cholera Transmission in Ouest Department of Haiti: Dynamic Modeling and the Future of the Epidemic |
| Q74733637 | Community interventions and the epidemic prevention potential |
| Q34633653 | Comparative effectiveness of different strategies of oral cholera vaccination in bangladesh: a modeling study |
| Q56830716 | Considerations for the design of vaccine efficacy trials during public health emergencies |
| Q36180204 | Containing Ebola at the Source with Ring Vaccination |
| Q43423229 | Containing a large bioterrorist smallpox attack: a computer simulation approach. |
| Q52028448 | Containing bioterrorist smallpox. |
| Q30351179 | Containing pandemic influenza at the source. |
| Q30340951 | Containing pandemic influenza with antiviral agents. |
| Q33606006 | Controlling cholera in the Ouest Department of Haiti using oral vaccines |
| Q21562250 | Controlling dengue with vaccines in Thailand |
| Q21144664 | Controlling endemic cholera with oral vaccines |
| Q43102994 | Correction: Cholera Transmission in Ouest Department of Haiti: Dynamic Modeling and the Future of the Epidemic |
| Q126179301 | Covariate-constrained randomization with cluster selection and substitution |
| Q91524562 | Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks |
| Q33913215 | Critical factors influencing the occurrence of Vibrio cholerae in the environment of Bangladesh |
| Q30412913 | Critical immune and vaccination thresholds for determining multiple influenza epidemic waves |
| Q51782604 | DESIGN OF VACCINE TRIALS DURING OUTBREAKS WITH AND WITHOUT A DELAYED VACCINATION COMPARATOR. |
| Q59245628 | Dengue seroprevalence in a cohort of schoolchildren and their siblings in Yucatan, Mexico (2015-2016) |
| Q41919030 | Dependency of Vaccine Efficacy on Pre-Exposure and Age: A Closer Look at a Tetravalent Dengue Vaccine |
| Q57163518 | Design and Analysis of Vaccine Studies |
| Q34211412 | Design and Evaluation of Prophylactic Interventions Using Infectious Disease Incidence Data from Close Contact Groups |
| Q33751472 | Design and interpretation of vaccine field studies. |
| Q91593723 | Design of vaccine efficacy trials during public health emergencies |
| Q92870239 | Designing a Study of Correlates of Risk for Ebola Vaccination |
| Q92889642 | Designing effective control of dengue with combined interventions |
| Q30367596 | Detecting human-to-human transmission of avian influenza A (H5N1). |
| Q64360030 | Determinants of transmission risk during the late stage of the West African Ebola epidemic |
| Q42616633 | Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children |
| Q34199593 | ESTIMATING WITHIN-HOUSEHOLD CONTACT NETWORKS FROM EGOCENTRIC DATA. |
| Q35987118 | ESTIMATING WITHIN-SCHOOL CONTACT NETWORKS TO UNDERSTAND INFLUENZA TRANSMISSION. |
| Q44101398 | Ebola vaccination - Authors' reply |
| Q30863896 | Ebola: mobility data |
| Q30371134 | Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. |
| Q64081724 | Effects of infection history on dengue virus infection and pathogenicity |
| Q34488529 | Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial |
| Q28051937 | Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) |
| Q30360764 | Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004 |
| Q43608789 | Efficacy of virucidal nasal tissues in interrupting familial transmission of respiratory agents. A field trial in Tecumseh, Michigan |
| Q73789830 | Efficiency of estimating vaccine efficacy for susceptibility and infectiousness: randomization by individual versus household |
| Q57936162 | El Tor cholera with severe disease: a new threat to Asia and beyond |
| Q35534867 | Emerging, evolving, and established infectious diseases and interventions |
| Q100433596 | Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials |
| Q57939849 | Epidemic and endemic cholera trends over a 33-year period in Bangladesh |
| Q88973950 | Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China |
| Q37288026 | Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics |
| Q59245629 | Epidemiology of dengue and other arboviruses in a cohort of school children and their families in Yucatan, Mexico: Baseline and first year follow-up |
| Q57163998 | Estimability and Interpretation of Vaccine Efficacy Using Frailty Mixing Models |
| Q72654091 | Estimates of the US health impact of influenza |
| Q45722262 | Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures |
| Q24655781 | Estimating influenza vaccine efficacy from challenge and community-based study data |
| Q97531139 | Estimating the establishment of local transmission and the cryptic phase of the COVID-19 pandemic in the USA |
| Q73502933 | Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control |
| Q52243115 | Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines. |
| Q57163525 | Evaluating Protective Effects of Vaccination |
| Q91565204 | Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study |
| Q88974705 | Evolving epidemiology of novel coronavirus diseases 2019 and possible interruption of local transmission outside Hubei Province in China: a descriptive and modeling study |
| Q30388996 | Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies |
| Q30350344 | Finding optimal vaccination strategies for pandemic influenza using genetic algorithms. |
| Q30227314 | FluTE, a publicly available stochastic influenza epidemic simulation model |
| Q56353070 | Forecasting the effectiveness of indoor residual spraying for reducing dengue burden |
| Q57163531 | Further Evaluation of Protective Effects |
| Q37449073 | Genetic variation of Vibrio cholerae during outbreaks, Bangladesh, 2010-2011. |
| Q33336603 | Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa |
| Q60193165 | Genomic epidemiology supports multiple introductions and cryptic transmission of Zika virus in Colombia |
| Q78177302 | Genomic epidemiology supports multiple introductions and cryptic transmission of Zika virus in Colombia. |
| Q56489846 | Guiding Vaccine Efficacy Trial Design During Public Health Emergencies: An interactive web-based decision support tool |
| Q35634754 | Hand, foot, and mouth disease in China: patterns of spread and transmissibility |
| Q37050010 | Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? |
| Q43520969 | Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? |
| Q95600705 | Household Secondary Attack Rate of COVID-19 and Associated Determinants |
| Q104467226 | Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis |
| Q34549663 | Household Transmission of Vibrio cholerae in Bangladesh |
| Q96612940 | Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study |
| Q35500457 | Household transmissibility of avian influenza A (H7N9) virus, China, February to May 2013 and October 2013 to March 2014. |
| Q98241609 | Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate |
| Q57163542 | Household-Based Studies |
| Q57163547 | Immunology and Early Phase Trials |
| Q35324845 | Increased isolation frequency of toxigenic Vibrio cholerae O1 from environmental monitoring sites in Haiti |
| Q55499955 | Intermediate levels of vaccination coverage may minimize seasonal influenza outbreaks. |
| Q30227297 | Intervention strategies for an influenza pandemic taking into account secondary bacterial infections |
| Q57163554 | Introduction and Examples |
| Q40039507 | Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness |
| Q57608821 | Markov Chains With Measurement Error: Estimating the `True' Course of a Marker of the Progression of Human Immunodeficiency Virus Disease |
| Q70222090 | Measures of the effects of vaccination in a randomly mixing population |
| Q126179329 | Methods for the estimation of direct and indirect vaccination effects by combining data from individual‐ and cluster‐randomized trials |
| Q30353646 | Mitigation strategies for pandemic influenza in the United States. |
| Q44257941 | Model-based estimation of vaccine effects from community vaccine trials |
| Q34759497 | Modeling Competing Infectious Pathogens from a Bayesian Perspective: Application to Influenza Studies with Incomplete Laboratory Results. |
| Q27006979 | Modeling cholera outbreaks |
| Q30368183 | Modeling targeted layered containment of an influenza pandemic in the United States. |
| Q95601898 | Modeling the impact of social distancing, testing, contact tracing and household quarantine on second-wave scenarios of the COVID-19 epidemic |
| Q44396514 | Modelling the female-to-male per-act HIV transmission probability in an emerging epidemic in Asia |
| Q98222311 | Modelling the impact of testing, contact tracing and household quarantine on second waves of COVID-19 |
| Q57163559 | Modes of Action and Time-Varying VE S |
| Q35987075 | Molecular Infectious Disease Epidemiology: Survival Analysis and Algorithms Linking Phylogenies to Transmission Trees |
| Q28471814 | Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread |
| Q44773899 | No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa |
| Q30382026 | One versus two doses: What is the best use of vaccine in an influenza pandemic? |
| Q30428994 | Optimal vaccine allocation for the early mitigation of pandemic influenza |
| Q74626132 | Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations |
| Q30396382 | Optimizing vaccine allocation at different points in time during an epidemic |
| Q57163564 | Overview of Vaccine Effects and Study Designs |
| Q39285591 | PREDICTIVE MODELING OF CHOLERA OUTBREAKS IN BANGLADESH. |
| Q103829214 | Placebo-Controlled Trials of Covid-19 Vaccines - Why We Still Need Them |
| Q30401049 | Planning for the control of pandemic influenza A (H1N1) in Los Angeles County and the United States |
| Q33812029 | Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2 |
| Q51980197 | Population-wide benefits of routine vaccination of children against influenza. |
| Q24812967 | Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges |
| Q52382959 | Probability of female-to-male transmission of HIV-1 in Thailand. |
| Q36634615 | Procedures for estimating transmission parameters from influenza epidemics: use of serological data |
| Q36030395 | Projected Impact of Dengue Vaccination in Yucatán, Mexico |
| Q26252071 | Projected spread of Zika virus in the Americas |
| Q34491128 | Public health. Community studies for vaccinating schoolchildren against influenza |
| Q46887189 | Public health. The cholera crisis in Africa |
| Q24278786 | Quantifying the Epidemiological Impact of Vector Control on Dengue |
| Q58593243 | Quantifying the risk of local Zika virus transmission in the contiguous US during the 2015-2016 ZIKV epidemic |
| Q38870792 | Quantitative assessment of the role of male circumcision in HIV epidemiology at the population level |
| Q59350196 | Questionable efficacy of the rVSV-ZEBOV Ebola vaccine - Authors' reply |
| Q57163569 | R 0 and Deterministic Models |
| Q57163574 | Randomization and Baseline Transmission |
| Q69689290 | Re: "Use of Modeling in Infectious Disease Epidemiology" |
| Q56762519 | Real-Time Assessment of the International Spreading Risk Associated with the 2014 West African Ebola Outbreak |
| Q54325318 | Reply to Aguiar and Stollenwerk. |
| Q59342754 | Reply to Vani et al.: Tuberculosis models and complexity |
| Q44105902 | Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report |
| Q80195639 | Safety of cold-adapted live influenza vaccine |
| Q30392554 | School opening dates predict pandemic influenza A(H1N1) outbreaks in the United States |
| Q34663046 | School-located influenza vaccination reduces community risk for influenza and influenza-like illness emergency care visits |
| Q49820319 | Seroprevalence of Dengue Antibodies in Three Urban Settings in Yucatan, Mexico |
| Q68867099 | Simulation of mechanisms of viral interference in influenza |
| Q70735997 | Simulation studies of influenza epidemics: assessment of parameter estimation and sensitivity |
| Q56762393 | Simulations for Designing and Interpreting Intervention Trials in Infectious Diseases |
| Q47106919 | Simulations for designing and interpreting intervention trials in infectious diseases |
| Q51336261 | Spatio-temporal coherence of dengue, chikungunya and Zika outbreaks in Merida, Mexico. |
| Q36124609 | Spatiotemporal dynamics of the Ebola epidemic in Guinea and implications for vaccination and disease elimination: a computational modeling analysis |
| Q39941822 | Spatiotemporal spread of the 2014 outbreak of Ebola virus disease in Liberia and the effectiveness of non-pharmaceutical interventions: a computational modelling analysis |
| Q29587277 | Spread of Zika virus in the Americas |
| Q30379858 | Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. |
| Q30350117 | Strategy for distribution of influenza vaccine to high-risk groups and children. |
| Q56146114 | Studies needed to address public health challenges of the 2009 H1N1 influenza pandemic: insights from modeling |
| Q34520391 | Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand |
| Q57163581 | Surrogates of Protection |
| Q57113790 | Tecumseh study of illness. XIII. Influenza infection and disease, 1976-1981 |
| Q94950112 | Temporal Confounding in the Test Negative Design |
| Q36206692 | The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study |
| Q100502849 | The TIRS trial: protocol for a cluster randomized controlled trial assessing the efficacy of preventive targeted indoor residual spraying to reduce Aedes-borne viral illnesses in Merida, Mexico |
| Q50584514 | The Tecumseh Study. XII. Enteric Agents in the Community, 1976-1981 |
| Q69714500 | The Tecumseh Study. XVI: Family and community sources of rotavirus infection |
| Q36202599 | The contribution of neighbours to an individual's risk of typhoid outcome |
| Q52028942 | The critical vaccination fraction for heterogeneous epidemic models. |
| Q26314683 | The dengue vaccine pipeline: Implications for the future of dengue control |
| Q72411112 | The ecological effects of individual exposures and nonlinear disease dynamics in populations |
| Q30398568 | The effect of age on transmission of 2009 pandemic influenza A (H1N1) in a camp and associated households |
| Q88973828 | The effect of travel restrictions on the spread of the 2019 novel coronavirus (2019-nCoV) outbreak |
| Q87745029 | The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak |
| Q35034544 | The effects of vector movement and distribution in a mathematical model of dengue transmission |
| Q26247279 | The epidemiology and transmissibility of Zika virus in Girardot and San Andres island, Colombia, September 2015 to January 2016 |
| Q30406360 | The global spread of drug-resistant influenza |
| Q27342983 | The global transmission and control of influenza |
| Q39593461 | The public health value of vaccines beyond efficacy: methods, measures and outcomes |
| Q30380569 | The transmissibility and control of pandemic influenza A (H1N1) virus. |
| Q39643221 | Towards a quantitative understanding of the within-host dynamics of influenza A infections |
| Q28393073 | Transmissibility and Pathogenicity of Ebola Virus: A Systematic Review and Meta-analysis of Household Secondary Attack Rate and Asymptomatic Infection |
| Q88919967 | Transmissibility of Norovirus in Urban Versus Rural Households in a Large Community Outbreak in China |
| Q36831589 | Transmission dynamics of Ebola virus disease and intervention effectiveness in Sierra Leone |
| Q51853905 | Understanding HIV epidemics: aggregate viral load metrics and 'smoking guns'. |
| Q57608819 | Use of immunological markers and continuous-time Markov models to estimate progression of HIV infection in homosexual men |
| Q30499938 | Vaccination strategies for epidemic cholera in Haiti with implications for the developing world |
| Q57163591 | Vaccine Effects on Post-Infection Outcomes |
| Q35532802 | Vaccine testing. Ebola and beyond |
| Q55113923 | What is the best control strategy for multiple infectious disease outbreaks? |
| Ira Longini | wikipedia | |
| Ira Longini | wikipedia |
Search more.